This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2004 by Charite University, Berlin, Germany.
Recruitment status was:  Recruiting
Information provided by:
Charite University, Berlin, Germany Identifier:
First received: September 15, 2005
Last updated: November 29, 2007
Last verified: February 2004
The purpose of this study is to evaluate the efficacy of levofloxacin to prevent bacterial infections in the postneutropenic period in patients who have undergone allogeneic stem cell transplantation (SCT).

Condition Intervention Phase
Malignancy Allogeneic Stem Cell Transplantation Drug: Levofloxacin Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With Levofloxacin as Prophylaxis for Bacterial Infections in Immunocompromised Patients After Allogeneic Transplantation of Hematopoietic Stem Cells

Resource links provided by NLM:

Further study details as provided by Charite University, Berlin, Germany:


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Allogeneic SCT
  • Postneutropenic period
  • Written consent

Exclusion Criteria:

  • Fever
  • Antibiotic therapy
  • Neutropenia
  • Refusal by the patient
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00215007

Contact: Igor Wolfgang Blau, Dr. 0049 30 8445 4430
Contact: Martin Schmidt-Hieber, Dr. 0049 30 8445 4555

Charite, CBF Recruiting
Berlin, Germany, 12200
Contact: Igor Wolfgang Blau         
Sponsors and Collaborators
Charite University, Berlin, Germany
Study Chair: Igor Wolfgang Blau, Dr. Charite, CBF, Berlin, Germany
  More Information Identifier: NCT00215007     History of Changes
Other Study ID Numbers: Levosta-CBF-02/04
Study First Received: September 15, 2005
Last Updated: November 29, 2007

Additional relevant MeSH terms:
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Anti-Bacterial Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors processed this record on September 21, 2017